Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1666 to 1680 of 1809 results for nice guidelines

  1. TearLab osmolarity system for diagnosing dry eye disease (MIB47)

    NICE has developed a medtech innovation briefing (MIB) on TearLab osmolarity system for diagnosing dry eye disease .

    Medtech innovation briefing
    Published
    15 December 2015

  2. Episcissors-60 show promise for mediolateral episiotomy. But there is currently not enough evidence to support the case for routine adoption in the NHS. Research is recommended to address uncertainties about the efficacy and safety of using Episcissors-60. This research should: - determine if using Episcissors-60 in addition to other care bundle measures is more effective in achieving an optimal episiotomy angle and in preventing episiotomy-related obstetric anal sphincter injuries (OASI) than standard episiotomy scissors - include patient-reported outcome measures - address potential equality considerations by ensuring patients at greatest risk of OASI are recruited - determine the relative cost of using Episcissors-60 compared with standard episiotomy scissors.

    at an optimal angle (45 to 60 degrees to the midline, according to NICE's guideline on intrapartum care) during delivery....

    Research recommendation
    Published
    17 March 2020

  3. NICE indicator process guide (PMG44)

    This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance and NICE accredited sources

  4. Baricitinib for treating severe alopecia areata (TA926)

    Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.

    Technology appraisal guidance
    Published
    25 October 2023
    View recommendations

    Sections for TA926

  5. Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

    Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.

    Technology appraisal guidance
    Published
    12 July 2017
    View recommendations

    Sections for TA456

  6. Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)

    Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.

    Technology appraisal guidance
    Published
    27 November 2013
    View recommendations

    Sections for TA300

  7. Cyanoacrylate glue for hernia mesh fixation (MIB301)

    NICE has developed a medtech innovation briefing (MIB) on cyanoacrylate glue for hernia mesh fixation .

    Medtech innovation briefing
    Published
    5 July 2022

  8. Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)

    Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in adults.

    Technology appraisal guidance
    Published
    15 December 2021
    View recommendations

    Sections for TA754

  9. Your voice is needed – my experience as a NICE committee member

    Dr Raja discusses the vital role frontline NHS colleagues have on our independent committees, and how you can get involved.

    News
    Last updated
    31 October 2024

  10. Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

    Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults

    Technology appraisal guidance
    Published
    28 November 2012
    View recommendations

    Sections for TA266

  11. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

    Technology appraisal guidance
    Last updated
    1 May 2024
    View recommendations

    Sections for TA540

  12. Pegunigalsidase alfa for treating Fabry disease (TA915)

    Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.

    Technology appraisal guidance
    Published
    4 October 2023
    View recommendations

    Sections for TA915

  13. Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    22 November 2023
    View recommendations

    Sections for TA931

  14. Early value assessment interim statement (PMG39)

    Early value assessment is a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need. It champions stronger partnership working between regulatory, healthcare and research organisations to benefit people and better support innovators while ensuring value for money for the NHS

  15. The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (MIB18)

    NICE has developed a Medtech Innovation Briefing (MIB) on the AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation

    Medtech innovation briefing
    Published
    12 February 2015